Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study
dc.contributor.author | Weinblat, M. | |
dc.contributor.author | Baranauskaite, A. | |
dc.contributor.author | Niebrzydowski, J. | |
dc.contributor.author | Dokoupilova, E. | |
dc.contributor.author | Zielinska, A. | |
dc.contributor.author | Sitek-Ziolkowska, K. | |
dc.contributor.author | Jaworski, J. | |
dc.contributor.author | Racewicz, A. | |
dc.contributor.author | Pileckyte, M. | |
dc.contributor.author | Jedrychowicz-Rosiak, K. | |
dc.contributor.author | Zhdan, V. | |
dc.contributor.author | Cheong, SY. | |
dc.contributor.author | Ghil, J. | |
dc.contributor.author | Ждан, Вячеслав Миколайович | |
dc.date.accessioned | 2018-09-25T07:17:32Z | |
dc.date.available | 2018-09-25T07:17:32Z | |
dc.date.issued | 2016-11-13 | |
dc.identifier.citation | Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study[Електронний ресурс] /M. Weinblatt, A. Baranauskaite, J. Niebrzydowski [at al.] // American College of Rheumatology. November 13, 2016. Режим доступу до журн.: https://acrabstracts.org/abstract/sustained-efficacy-and-comparable-safety-and-immunogenicity-after-transition-to-sb5-an-adalimumab-biosimilar-vs-continuation-of-sb5-or-reference-adalimumab-humira-in-patients-with-rheumatoi | uk_UA |
dc.identifier.uri | https://repository.pdmu.edu.ua/handle/123456789/8673 | |
dc.language.iso | en | uk_UA |
dc.publisher | American College of Rheumatology | uk_UA |
dc.subject | biosimilars | uk_UA |
dc.title | Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study | uk_UA |
dc.type | Article | uk_UA |
Файли
Контейнер файлів
1 - 1 з 1
Ескіз недоступний
- Назва:
- EfficacySafetySB5Adalimumab_RheumatoidArthritis.pdf
- Розмір:
- 83.71 KB
- Формат:
- Adobe Portable Document Format
- Опис:
Ліцензійна угода
1 - 1 з 1
Ескіз недоступний
- Назва:
- license.txt
- Розмір:
- 4.12 KB
- Формат:
- Item-specific license agreed upon to submission
- Опис: